Marshall Wace
VRTX icon

Marshall Wace’s Vertex Pharmaceuticals VRTX Stock Holding History

Marshall Wace’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$893K Buy
2,000
+800
+67% +$373K ﹤0.01% 2192
2025
Q4 		$544K Buy
1,200
+400
+50% +$172K ﹤0.01% 2203
2025
Q3 		$313K Buy
+800
New +$334K ﹤0.01% 2412

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace's VRTX Position: Q1 2026 in Review

Marshall Wace increased its Vertex Pharmaceuticals (VRTX) stake by 55% in Q1 2026, buying an estimated $52.7M and bringing the position to 317,058 shares worth $142M. The position accounts for 0.14% of the portfolio, ranked #107.

Marshall Wace first reported a position in VRTX in Q2 2014 and has held it in 41 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Marshall Wace held 317,058 shares of Vertex Pharmaceuticals worth $142M as of Q1 2026.
  • Marshall Wace bought 113,026 Vertex Pharmaceuticals shares in Q1 2026, an estimated $52.7M.
  • Vertex Pharmaceuticals made up 0.14% of Marshall Wace's portfolio in Q1 2026, its #107 holding.
  • Marshall Wace first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 41 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.